Blood‐based biopsies—clinical utility beyond circulating tumor cells. Issue 12 (19th October 2018)

• Record Type: Journal Article
• Authors: Tang, Cha‐Mei; Zhu, Peixuan; Li, Shuhong; Makarova, Olga V.; Amstutz, Platte T.; Adams, Daniel L.
• Other Names: Terstappen Leon W.M.M. guestEditor.
• Is Part Of: Cytometry. Volume 93:Issue 12(2018)
• Page Start: 1246
• Page End: 1250
• Publication Date: 2018-10-19
• Subjects: Cancer‐associated macrophage‐like cells -- CAMLs -- liquid pathology -- circulating tumor cells -- CTCs -- microfiltration -- microfilters -- CellSieve -- liquid biopsy -- liquid cell biopsy -- blood‐based biopsy; Flow cytometry -- Periodicals; Imaging systems in biology -- Periodicals; Imaging systems in medicine -- Periodicals; Diagnostic imaging -- Periodicals; 571.605
• DOI: 10.1002/cyto.a.23573
• Languages: English
• ISSNs: 1552-4922

Abstract

Abstract: Circulating tumor cells (CTCs), epithelial–mesenchymal transition (EMT) cells, as well as a number of circulating cancer stromal cells (CStCs) are known to shed into the blood of cancer patients. Individually, and together, these cells provide biological and clinical information about the cancers. Filtration is a method used to isolate all of these cells, while eliminating red and white blood cells from whole peripheral blood. We have previously shown that accurate identification of these cell types is paramount to proper clinical assessment by describing the overlapping phenotypes of CTCs to one such CStC, the cancer‐associated macrophage‐like cell (CAML). We report that CAMLs possess a number of parallel applications to CTCs but have a broader range of clinical utility, including cancer screening, companion diagnostics, diagnosis, prognosis, monitoring of treatment response, and detection of recurrence. © 2018 The Authors. Cytometry Part A published by Wiley Periodicals, Inc. on behalf of ISAC.